Advanced in Multiple Myeloma

Dr. Bipinkumar R. Amin

Hematology Oncology | Hematology | Oncology
Prairie Lakes Health Care System Inc
401 9th Ave Nw, 
Watertown, SD 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Advanced in Multiple Myeloma
Prairie Lakes Health Care System Inc
401 9th Ave Nw, 
Watertown, SD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bipinkumar Amin is a Hematologist Oncology specialist and a Hematologist in Watertown, South Dakota. Dr. Amin is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Thrombocytopenia, Melanoma, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Amin is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Multiple Myeloma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in SD
Hospital Affiliations
Prairie Lakes Healthcare System, Inc
Sanford Hospital Webster - Cah
Coteau Des Prairies Health Care System
Milbank Area Hospital/avera Health
Languages Spoken
English
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Avera Health
  • HMO
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
DAKOTACARE
  • HMO
  • INSURANCE PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Primewest Health System
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

PRAIRIE LAKES HEALTH CARE SYSTEM INC
401 9th Ave Nw, Watertown, SD 57201
Other Locations
PRAIRIE LAKES HEALTH CARE SYSTEM INC
900 2nd Ave, Madison, MN 56256

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)
A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)
Enrollment Status: Recruiting
Publish Date: April 07, 2023
Intervention Type: Drug
Study Drugs: DPX-Survivac, Pembrolizumab, CPA
Study Phase: Phase 2
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Tomivosertib, Pembrolizumab
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
Enrollment Status: Completed
Publish Date: September 20, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 2
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 5 Less Clinical Trials

1 Total Publications

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 04, 2011
Similar Doctors
Elaine M. Kaime
Experienced in Multiple Myeloma
Dr. Elaine M. Kaime
Hematology Oncology | Hematology | Oncology
Experienced in Multiple Myeloma
Dr. Elaine M. Kaime
Hematology Oncology | Hematology | Oncology

Sanford Health Network

701 3rd Ave S, 
Clear Lake, SD 
 (24.0 miles away)
605-874-2141
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Elaine Kaime is a Hematologist Oncology specialist and a Hematologist in Clear Lake, South Dakota. Dr. Kaime has been practicing medicine for over 43 years and is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. Her top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Colorectal Cancer, and Gliomatosis Cerebri. Dr. Kaime is currently accepting new patients.

Experienced in Multiple Myeloma
Dr. Ferdinand E. Addo
Hematology Oncology | Hematology | Oncology
Experienced in Multiple Myeloma
Dr. Ferdinand E. Addo
Hematology Oncology | Hematology | Oncology
401 9th Ave Nw, 
Watertown, SD 
 (0.1 miles away)
605-882-6800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ferdinand Addo is a Hematologist Oncology specialist and a Hematologist in Watertown, South Dakota. Dr. Addo is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Follicular Lymphoma, and Myelodysplastic Syndrome (MDS). Dr. Addo is currently accepting new patients.

Experienced in Multiple Myeloma
Dr. Vijay P. Rao
Hematology Oncology | Oncology | Hematology
Experienced in Multiple Myeloma
Dr. Vijay P. Rao
Hematology Oncology | Oncology | Hematology

Prairie Lakes Health Care System Inc

1282 Walnut St, 
Dawson, MN 
 (51.6 miles away)
320-769-4323
Languages Spoken:
English, Hindi, Telugu, Urdu
See accepted insurances
Accepting New Patients

Vijay Rao is a Hematologist Oncology specialist and an Oncologist in Dawson, Minnesota. Dr. Rao is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Inflammatory Breast Cancer, Pleuropulmonary Blastoma, Squamous Cell Lung Carcinoma, and ALK-Positive Non-Small Cell Lung Cancer. Dr. Rao is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Amin's expertise for a condition
ConditionClose
    View All 28 Advanced Conditions
    View All 83 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile